A Spanish dermatologist suggests sulforaphane for androgenetic alopecia (AGA) due to its potential to remove DHT metabolites, though high dosages are needed. A topical formulation might be possible.
Exosomes are not effective for long-term hair regrowth, with users reporting temporary improvements or no noticeable change. Effective treatments include Dutasteride, Finasteride, Minoxidil, and RU58841, with other options like CB-03-01 and Fluridil offering limited benefits.
User discusses potential hair loss treatment SCUBE3 and shares mixed opinions on its effectiveness. One user reports positive results after applying SCUBE3 following microneedling.
The conversation discusses hair loss treatments, specifically Brassica oleracea extract, glucosinolates, and sulforaphane, and their potential to promote hair growth. Users also mention minoxidil and finasteride as existing treatments.
A satirical post where someone claims to have developed a radioactive isotope scalp serum using Polonium-210 that outperforms Minoxidil and finasteride for hair regrowth. The serum reportedly stimulates DNA repair in hair follicles, leading to significant hair density increase, but the post is met with skepticism and concerns about safety.
Switching generic finasteride manufacturers can reduce side effects while maintaining effectiveness. Different fillers in generics may affect bioavailability and cause varying side effects.
A dermatologist checked for hereditary hair loss using blood tests and plans to perform a trichogram. The user had slightly low Vitamin D3 levels, and the trichogram may help confirm androgenetic alopecia.
The conversation discusses hair loss treatments, focusing on Tsuji's hair cloning and Shiseido's RCH-01, with skepticism about their effectiveness on humans. It compares these to PRP, noting PRP's higher efficacy in studies.
Exosome treatment for hair loss, derived from umbilical cord stem cells, is being considered as an option before a hair transplant. Users discuss the need for ongoing maintenance and share experiences with different exosome sources, including plant-derived options.
Combining Minoxidil with peptide serums like Redensyl, Procapil, and Capixyl is more effective for hair growth than using Minoxidil alone, increasing hair density and thickness. However, some users are skeptical about the effectiveness of peptides, suggesting other ingredients or factors might contribute to the results.
The user noticed new baby hairs after using sulforaphane but is still experiencing shedding. They are seeking a supplement to stop shedding, possibly grape seed extract.
The user has been taking oral minoxidil, dutasteride, and biotin for 3 months and noticed changes in hair texture, suggesting potential regrowth or stabilization. Baby hairs and increased hair density are seen as positive signs.
Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.
The conversation discusses the use of Minoxidil and finasteride for hair loss and explores the potential of Geranium sibiricum extract as a safer alternative. It highlights the difficulty in finding this specific extract and suggests considering other plants with similar compounds, like Indian gooseberry.
Stem cell-related treatments and drugs like RCGD423 and WAY are being tested for hair growth. Clinics are conducting tests on patients who haven't had previous treatments.
A user created a free AI-powered hair transplant simulator to help visualize post-transplant results, seeking feedback and offering it as a tool for clinics. Users discussed its usefulness, limitations, and the requirement for email and phone verification to prevent abuse.
Hair loss affects confidence, with discussions on treatments like finasteride, minoxidil, and RU58841. Emphasis is placed on self-acceptance and building confidence beyond appearance.
User tried oral finasteride, topical finasteride, topical dutasteride, and RU58841 but experienced side effects. They discuss upcoming treatments like clascoterone, pyrilutamide, gt20029, and KY19382 as potential options.
The conversation discusses various hair loss treatments, including pyrilutamide, RU58841, topical dutasteride, oral minoxidil, and oral finasteride/dutasteride. It also mentions potential treatments like PP405, Verteporfin, GT20029, and AMP303.
The conversation discusses a patent filed by Shiseido for cloning Dermal Papilla (DP) cells to treat hair loss. The method involves using viral vectors to maintain the cells' growth-inducing properties, differing from Replicel's approach with Dermal Sheath Cup (DSC) cells.
A 19-year-old male with no family history of androgenetic alopecia (AGA) is experiencing hair loss and considering using a topical minoxidil and finasteride mixture. Despite low vitamin D levels and normal DHT serum levels, he seeks confirmation of AGA before starting treatment.
A Swiss product called Redensyl, which is supposed to target hair follicle stem cells and has recently been marketed in Europe. The post inquires if anyone has had any experience with the product.
Copper peptides, specifically GHK-Cu, are being considered for hair regrowth, though skepticism exists due to questionable product sources. Users suggest finding reputable sources for potential benefits, while acknowledging traditional treatments like Minoxidil and Finasteride.
The conversation is about a user experiencing hair thinning and considering exosome treatment after being advised against a hair transplant. The user seeks advice from others who may have tried exosomes for hair loss.
ET-02, a PAI-1 inhibitor, is not proven to be more effective than Minoxidil for hair loss. Other treatments like finasteride, dutasteride, PP405, and AMP-303 are also discussed, focusing on cellular senescence and oxidative stress.
The conclusion of the conversation is that CosmeRna may not be an effective treatment for hair loss compared to topical minoxidil 2%. It is suggested to wait for more reviews before purchasing it.
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.